Summary
For Year 2026-27, Alivus Life Sciences reports the following shareholding: Total Promoters at 74.87%, Mutual Fund at 5.63%, Insurance at 0.27%, Foreign Institutional Investors at 5.3%, Domestic Institutional Investors at 1.37%, and Retail at 12.56%. This breakdown provides a quick snapshot of ownership distribution for Alivus Life Sciences in 2026-27.
Alivus Life Sciences FAQs
As of 04-2026, the promoter shareholding in Alivus Life Sciences stands at 74.87% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Alivus Life Sciences is 5.3% and 1.37% respectively.
The retail shareholding of the Alivus Life Sciences is 12.56%.
Changes in shareholding patterns of Alivus Life Sciences can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Alivus Life Sciences are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Alivus Life Sciences Associated Pages
